间充质干细胞治疗早期糖尿病视网膜病变研究进展

• 作 者: 陈莉
• 机 构: 300020,天津市眼科医院天津医科大学眼科临床学院天津市眼科学与视觉科学重点实验室天津市眼科研究所
• 出 处: 中华实验眼科杂志
• 发表日期: 2016年7期
• 关键词: Diabetic retinopathy Mesenchymal stem cells Transplantation pathway Treatment Re

糖尿病视网膜病变(DR)是糖尿病的主要并发症之一,其病变主要包括微血管病变和神经元功能的损害.治疗早期DR的研究从未间断,包括药物、生物制剂等,其中间充质干细胞(MSCs)作为一种具有广阔应用前景的组织工程细胞得到越来越多的关注.MSCs具有多向分化及免疫调节等能力,MSCs治疗DR可能有多种机制,通过MSCs体外培养和动物体内实验的研究发现,不同途径移植MSCs对DR进行早期干预后,其对DR的抗炎及神经保护等作用可改善DR视网膜功能,延缓DR的发展.就研究进展作一综述.“,”Diabetic retinopathy (DR) is one of the major complications of diabetes.It includes microvascular disease and neuronal function change.For the early treatment of DR,there are a variety of drugs and biologic preparations,including mesenchymal stem cells (MSCs).As a kind of tissue engineering cell,it has broad prospects and gradually receives increasing attention.MSCs have strong ability of multi-directional differentiation and immuneregulation.Treating DR by MSCs may have a variety of mechanisms.Anti-inflammatory and neuroprotective effects of DR have been confirmed.According to the studies of MSCs in vitro and in vivo experiments.The researchers found that different MSCs transplantation approaches can improve retinal function in early DR and delay the development of DR.This paper was to a review on the research progress.